Acquisitions, Payments, Agreements, and Commercial Launches - Analyst Notes on Questcor, Isis, BD, CareFusion and Agilent

NEW YORK, June 27, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals Inc (NASDAQ: QCOR), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), Becton, Dickinson and Co. (NYSE: BDX), CareFusion Corporation (NYSE: CFN) and Agilent Technologies Inc. (NYSE: A). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4197-100free.

--
Questcor Pharmaceuticals Inc Analyst Notes
On June 23, 2014, Questcor Pharmaceuticals Inc (Questcor) announced the closing of the transaction to acquire international rights to Synacthen® and Synacthen® Depot from Novartis Pharma AG and Novartis AG in some countries outside the U.S. According to the Company, Synacthen® (tetracosactide) is a synthetic 24 amino acid melanocortin peptide, while Synacthen® Depot is a depot formulation of Synacthen. Both products, though approved outside the U.S. for multiple indications such as certain autoimmune and inflammatory conditions and also for diagnostic use, have never been developed or approved for patients in the U.S. Questcor added that it is currently engaged in the pre-clinical development for Synacthen in the U.S. The Company stated that under the transaction agreements, Questcor will have the right to develop, market, manufacture, distribute, sell, and commercialize Synacthen worldwide with the exception of 13 European countries where Novartis has previously granted rights to a third party. The full analyst notes on Questcor are available to download free of charge at:

http://www.analystsreview.com/Jun-27-2014/QCOR/report.pdf

--
ISIS Pharmaceuticals, Inc. Analyst Notes
On June 24, 2014, ISIS Pharmaceuticals, Inc. (Isis) announced that it earned $1 million as milestone payment from GlaxoSmithKline (GSK) in relation to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP). The Company informed that ISIS-TTRRx is an intense drug in development with GSK to treat transthyretin amyloidosis, a severe and rare genetic disease that is characterized by the progressive dysfunction of peripheral nerve and/or heart tissues. Isis stated that including this $1 million milestone payment, which is also the fourth of the $50 million in milestone payments the Company is eligible to receive through the progression of the Phase 2/3 study, it has now generated a total of $26 million in upfront milestone payments for advancing ISIS-TTRRx. The full analyst notes on Isis are available to download free of charge at:

http://www.analystsreview.com/Jun-27-2014/ISIS/report.pdf

--
Becton, Dickinson and Co. Analyst Notes
On June 17, 2014, BD Medical, a segment of Becton, Dickinson and Co. (BD), announced an agreement with The University of Texas MD Anderson Cancer Center to install the BD Cato™ Workflow Solution, a system that enhances safety and workflow efficiency in medication preparation through the use of gravimetric and barcoding technology. According to the Company, this agreement makes MD Anderson Cancer Center the first institution in the U.S. to implement the BD Cato System, and will incorporate the system into its outpatient infusion pharmacies, including community-based locations. The full analyst notes on BD are available to download free of charge at:

http://www.analystsreview.com/Jun-27-2014/BDX/report.pdf

--
CareFusion Corporation Analyst Notes
On June 18, 2014, CareFusion Corporation (CareFusion) announced the commercial launch of its new and one of its most comprehensive micro-laparoscopic line of surgical instruments. According to the Company, the CareFusion MicroLap is a reusable platform that features a full line of access devices, scopes, accessories, and hand instruments that are as small as 2.7mm diameter and leave an incision scar half the size of the standard (5mm or 10mm) laparoscopic instruments. The Company stated that this eliminates the need to close the incision site with sutures in some procedures and results to a virtually scar-less procedure. The full analyst notes on CareFusion are available to download free of charge at:

http://www.analystsreview.com/Jun-27-2014/CFN/report.pdf

--
Agilent Technologies Inc. Analyst Notes
On June 23, 2014, Agilent Technologies Inc. (Agilent) and Bruker Corp. announced an agreement to provide customers with compatible chromatographic data system software. According to the Company, under the agreement, the two companies will exchange information to develop instrument drivers for their respective gas chromatographs through which, both companies' GC systems may be interfaced and controlled by either Agilent's OpenLAB Chromatography Data System or Bruker's Compass CDS. Agilent stated that this exchange will enable customers to preserve their investments in workflows and increase their efficiency in operating procedures. Agilent added that later this year, OpenLAB CDS software will be able to support Bruker's 3000- and 4000-series gas chromatographs including its latest SCION 436 and 456 models, and in turn, Compass CDS software drivers will support Agilent's 5890, 6890, 7890, and similar gas chromatographs. Agilent and Bruker plan to make these drivers available by the end of 2014. The full analyst notes on Agilent are available to download free of charge at:

http://www.analystsreview.com/Jun-27-2014/A/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review